The kunitz protease inhibitor domain of protease nexin-2 inhibits factor XIa and murine carotid artery and middle cerebral artery thrombosis.
Coagulation factor XI (FXI) plays an important part in both venous and arterial thrombosis, rendering FXIa a potential target for the development of antithrombotic therapy. The kunitz protease inhibitor (KPI) domain of protease nexin-2 (PN2) is a potent, highly specific inhibitor of FXIa, suggesting its possible role in the inhibition of FXI-dependent thrombosis in vivo. Therefore, we examined the effect of PN2KPI on thrombosis in the murine carotid artery and the middle cerebral artery. Intravenous administration of PN2KPI prolonged the clotting time of both human and murine plasma, and PN2KPI inhibited FXIa activity in both human and murine plasma in vitro. The intravenous administration of PN2KPI into WT mice dramatically decreased the progress of FeCl(3)-induced thrombus formation in the carotid artery. After a similar initial rate of thrombus formation with and without PN2KPI treatment, the propagation of thrombus formation after 10 minutes and the amount of thrombus formed were significantly decreased in mice treated with PN2KPI injection compared with untreated mice. In the middle cerebral artery occlusion model, the volume and fraction of ischemic brain tissue were significantly decreased in PN2KPI-treated compared with untreated mice. Thus, inhibition of FXIa by PN2KPI is a promising approach to antithrombotic therapy.
Sol Sherry Thrombosis Research Center, Temple University School of Medicine, 3400 North Broad St, Philadelphia, PA 19140, USA.
Wenman
W
Wu
Hongbo
H
Li
Duraiswamy
D
Navaneetham
Zachary W
ZW
Reichenbach
Ronald F
RF
Tuma
Peter N
PN
Walsh
D016564:Amyloid beta-Protein Precursor / Q000737:chemistry / Q000235:genetics / Q000494:pharmacology*; D000818:Animals; D000925:Anticoagulants / Q000494:pharmacology; D001760:Bleeding Time; D001777:Blood Coagulation / Q000187:drug effects / Q000502:physiology; D002341:Carotid Artery Thrombosis / Q000097:blood* / Q000188:drug therapy*; D004195:Disease Models, Animal; D015195:Drug Design; D015945:Factor XIa / Q000037:antagonists & inhibitors* / Q000378:metabolism; D005260:Female; D006801:Humans; D020244:Infarction, Middle Cerebral Artery / Q000097:blood* / Q000188:drug therapy*; D007275:Injections, Intravenous; D051379:Mice; D008810:Mice, Inbred C57BL; D017434:Protein Structure, Tertiary / Q000502:physiology; D011994:Recombinant Proteins / Q000737:chemistry / Q000235:genetics / Q000494:pharmacology
D016564:Amyloid beta-Protein Precursor; D000925:Anticoagulants; D011994:Recombinant Proteins; D015945:Factor XIa